Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.

Simple item page
dc.contributor.authorDatta, N Ren_US
dc.contributor.authorRajkumar, Aen_US
dc.contributor.authorBasu, Ren_US
dc.date.accessioned2009-05-28T06:21:19Z
dc.date.available2009-05-28T06:21:19Z
dc.date.issued2003-10-13en_US
dc.description.abstractBACKGROUND: Summated dose-intensity (SDI) of chemotherapy regimen could influence the outcome in malignancies. AIMS: To evaluate the implication of SDI and identify key drugs for loco-regional response in locally advanced breast cancer (LABC). Settings and design: This retrospective study was based on audit of records of LABC patients who had received neoadjuvant chemotherapy (NACT). MATERIAL AND METHODS: Actual unit dose-intensity (UDI) of each drug and corresponding SDI of every doxorubicin (n=116 cycles) or non-doxorubicin (n=110 cycles) based NACT received by 42 patients of LABC were summated. Cumulative dose-intensity (CDI) for individual drugs and cumulative SDI (CSDI) for the entire course of NACT were estimated and correlated with quantum of primary tumor, axillary and supraclavicular nodal responses. STATISTICAL ANALYSIS USED: Two-sided chi-square, t-test, step-wise regression was used. RESULTS: Dose-response curve between CSDI and corresponding responses for both primary and lymph nodes were sigmoid in shape for both doxorubicin or non-doxorubicin based NACT. Curves were best fitted using a cubic fit for all patients (r2 = 0.82, 0.84 and 0.93 for primary tumor, axillary and supraclavicular lymph nodes respectively). CSDI emerged as an important prognosticators for both primary (P<0.001) and nodal (P<0.001) responses. Individually, CDI of 5-fluorouracil for primary (P<0.001), CDIs of doxorubicin (P<0.001) and methotrexate (P=0.006) for axillary nodes and CDI of cyclophosphamide (P=0.001) for supraclavicular nodes were significant. CONCLUSIONS: Loco-regional responses in LABC are dependent on CSDI of NACT regimen. Drugs for high-dose intensification protocols could be identified and chosen based on the impact of CDI of individual drugs in NACT.en_US
dc.description.affiliationDepartment of Radiotherapy, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India. nrdatta@sgpgi.ac.inen_US
dc.identifier.citationDatta NR, Rajkumar A, Basu R. Summated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications. Indian Journal of Cancer. 2003 Oct-Dec; 40(4): 127-34en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/49708
dc.language.isoengen_US
dc.source.urihttps://www.indianjcancer.comen_US
dc.subject.meshAdulten_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols --administration & dosageen_US
dc.subject.meshAxillaen_US
dc.subject.meshBreast Neoplasms --drug therapyen_US
dc.subject.meshChemotherapy, Adjuvanten_US
dc.subject.meshCyclophosphamide --administration & dosageen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshDoxorubicin --administration & dosageen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil --administration & dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshLymph Nodes --drug effectsen_US
dc.subject.meshLymphatic Metastasisen_US
dc.subject.meshMethotrexate --administration & dosageen_US
dc.subject.meshNeoadjuvant Therapyen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshPrognosisen_US
dc.subject.meshReceptors, Estrogen --metabolismen_US
dc.subject.meshReceptors, Progesterone --metabolismen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleSummated chemotherapy dose-intensity versus loco-regional response in locally advanced breast cancer: its possible implications.en_US
dc.typeClinical Trialen_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
Indian Journal of Cancer